Latest 3 stories · newest Nov 4, 2026
Mineralys reported 46% of patients met AHA guidelines in Launch-HTN at Week 12. The positive data bolsters investor confidence ahead of a key FDA decision for its hypertension drug, lorundrostat.
Mineralys Therapeutics entered into an underwriting agreement on June 3, 2026 to sell 5,660,378 shares of common stock through BofA Securities, Goldman Sachs, and Evercore. The offering follows an effective shelf registration statement and represents a capital raise for the clinical-stage therapeuti…
The same MLYS feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/MLYS/newsSTART FREE